Pooled Analysis of Valve‐in‐Valve and Valve‐in‐Ring Transcatheter Mitral Valve Replacement Using the SAPIEN Valve
- 6 October 2026
- journal article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (19) , e044789
Abstract
Background: Transcatheter mitral valve replacement (TMVR) using the Sapien (Edwards Lifesciences, Irvine, CA) transcatheter heart valve has become the preferred treatment for high‐risk patients with failed mitral bioprosthetic valves or prior surgical mitral valve repairs. Differences in anatomy and procedural complexity between valve‐in‐valve TMVR (ViV‐TMVR) and valve‐in‐ring TMVR (ViR‐TMVR) may influence clinical outcomes. Methods: We systematically searched OVID Medline, Embase, SCOPUS, Web of Science, and Cochrane for studies published between 2015 and 2022 comparing ViV‐TMVR and ViR‐TMVR. The primary end point was 30‐day all‐cause mortality. Secondary outcomes included in‐hospital mortality, stroke, acute kidney injury, major bleeding, reintervention, left ventricular outflow tract obstruction, and device embolization. Random‐effects models were used to pool outcomes. Results: Eight studies including 1947 patients (ViV‐TMVR: 1435; ViR‐TMVR: 512) were analyzed. Patients undergoing ViV‐TMVR were older and had a greater baseline comorbidity burden. No significant differences were observed in 30‐day mortality (odds ratio [OR]: 0.70 [95% CI: 0.47–1.05]; I 2 =0%) or in‐hospital mortality (OR: 1.05 [95% CI: 0.34–3.21]; I 2 =3%). Similarly, stroke, major bleeding, and device embolization did not differ significantly between groups. However, ViV‐TMVR was associated with lower rates of left ventricular outflow tract obstruction (OR: 0.30 [95% CI: 0.18–0.51]), reintervention (OR: 0.19 [95% CI: 0.13–0.30]), and acute kidney injury (OR: 0.51 [95% CI: 0.29–0.90]), with no significant heterogeneity. Conclusions: Compared with ViR‐TMVR, ViV‐TMVR was associated with lower rates of left ventricular outflow tract obstruction, reintervention, and acute kidney injury, whereas mortality and other major complications were comparable. These findings may inform patient selection and procedural planning for transcatheter mitral valve interventions.Keywords
This publication has 36 references indexed in Scilit:
- Meta-Analysis Comparing Valve-in-Valve Transcatheter Mitral Valve Replacement Versus Redo Surgical Mitral Valve Replacement in Degenerated Bioprosthetic Mitral ValveThe American Journal of Cardiology, 2022
- Five‐year outcomes of transcatheter mitral valve implantation and redo surgery for mitral prosthesis degenerationCatheterization and Cardiovascular Interventions, 2022
- Short‐ and mid‐term outcomes in percutaneous mitral valve replacement using balloon expandable valvesCatheterization and Cardiovascular Interventions, 2021
- Hemolysis after transcatheter mitral valve replacement in degenerated bioprostheses, annuloplasty rings, and mitral annular calcification: Incidence, patient characteristics, and clinical outcomesCatheterization and Cardiovascular Interventions, 2021
- Acute Kidney Injury After Percutaneous Edge-to-Edge Mitral RepairJACC, 2020
- One-Year Outcomes of Mitral Valve-in-Valve Using the SAPIEN 3 Transcatheter Heart ValveJAMA Cardiology, 2020
- Clinical Outcomes of Mitral Valve Reoperations in the United States: An Analysis of The Society of Thoracic Surgeons National DatabaseThe Annals of Thoracic Surgery, 2019
- Early Outcomes of Percutaneous Transvenous Transseptal Transcatheter Valve Implantation in Failed Bioprosthetic Mitral Valves, Ring Annuloplasty, and Severe Mitral Annular CalcificationJACC: Cardiovascular Interventions, 2017
- Transcatheter Valve-in-Valve and Valve-in-Ring for Treating Aortic and Mitral Surgical Prosthetic DysfunctionJACC, 2015
- Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statementInternational Journal of Surgery, 2010